What are the treatments for breast lymph nodes?

Breast lymphoma is a common disease currently. The primary disease is breast lymphoma, which is mostly malignant tumors clinically. Patients with breast lymphoma should be diagnosed in time after the onset of the disease to avoid the spread of the disease throughout the body. Active treatment should be carried out according to the patient's medical history. Some patients have symptoms of fever and pain for a period of time, which requires timely medication to suppress. Antibiotics and antibody elements should be used to prevent the spread of cells.

The diagnostic criteria for primary breast lymphoma are:

(1) Sufficient pathological specimens;

(2) Pathological evidence confirms a close relationship between breast tissue and lymphoma infiltration;

(3) No evidence of concurrent systemic disseminated disease; (4) No history of lymphoma other than the breast.

Literature reports that the median age of patients is between 50 and 69 years old, and both adolescents and the elderly can develop the disease. The onset age of Asian patients is 39 to 51 years old, which is lower than that of patients in European and American countries.

The disease is often characterized by a hard lump in the breast, which is reported to be more common on the right side. It may or may not be accompanied by lymphadenopathy, and some patients have fever and pain. Patients with diffuse involvement of both breasts have a higher risk of malignancy.

The preoperative clinical manifestations of PBL patients are difficult to differentiate from breast cancer and mainly rely on pathological diagnosis and classification. The methods for obtaining pathology include puncture biopsy and surgical biopsy. Rapid intraoperative frozen sections can only be used to diagnose malignant tumors, which are ultimately confirmed by immunohistochemistry. Therefore, intraoperative frozen sections are not very helpful for diagnosis.

For the treatment of primary breast lymphoma, most scholars do not advocate radical mastectomy, but recommend breast-preserving lumpectomy assisted by postoperative radiotherapy and chemotherapy.

Due to the small number of cases, the prognostic factors of this disease are still unclear. It may be related to the clinical stage of the tumor, pathological type, treatment method and the size of the primary tumor. Literature reports that the 5-year survival rate of primary breast lymphoma is 43% to 85%. Among them, stage I is 61% to 89%, and stage II is 0 to 50%.

The main reason for the failure of treatment of breast malignant lymphoma is distant metastasis. Common metastatic sites are the contralateral breast, brain, lung, liver, spleen and distant lymph nodes. Chemotherapy is important in preventing tumor metastasis and spread, but up to 60% of patients still experience distant metastasis even after chemotherapy. Therefore, how to further reduce distant metastasis needs further study.